Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial

Date
2021
Author
Mccue, S.
Mahr, A.
Takeno, M.
Kim, D. Y.
Saadoun, D.
DİRESKENELİ, RAFİ HANER
Melikoglu, M.
Cheng, S.
Paris, M.
Yazici, Y.
Chen, M.
Hatemi, G.
Metadata
Show full item record
Abstract
Objective. This study assessed the efficacy and safety of apremilast for the oral ulcers associated with Behcet's syndrome (BS) up to 64 weeks.
URI
http://hdl.handle.net/20.500.12627/172224
Collections